| Literature DB >> 22461981 |
Jennifer Anne Larosa1, Noeen Ahmad, Monica Feinberg, Monica Shah, Roseann Dibrienza, Sean Studer.
Abstract
Introduction. Diagnostic and therapeutic guidelines, organized as sepsis bundles, have been shown to improve mortality, but timely and consistent implementation of these can be challenging. Our study examined the use of a screening tool and an early alert system to improve bundle compliance and mortality. Methods. A screening tool was used to identify patients with severe sepsis or septic shock and an overhead alert system known as Code SMART (Sepsis Management Alert Response Team) was activated at the physician's discretion. Data was collected for 6 months and compliance with bundle completion and mortality were compared between the Code SMART and non-Code SMART groups. Results. Fifty eight patients were enrolled -34 Code SMART and 24 non-Code SMART. The Code SMART group achieved greater compliance with timely antibiotic administration (P < 0.001), lactate draw (P < 0.001), and steroid use (P = 0.02). Raw survival and survival adjusted for age, leucopenia, and severity of illness scores, were greater in the Code SMART group (P < 0.05, P = 0.03, and P = 0.01). Conclusions. A screening tool and an alert system can improve compliance with sepsis bundle elements and improve survival from severe sepsis and septic shock.Entities:
Year: 2012 PMID: 22461981 PMCID: PMC3296210 DOI: 10.1155/2012/980369
Source DB: PubMed Journal: Crit Care Res Pract ISSN: 2090-1305
Evaluation for sepsis—screening Tool.
|
|
| (1) Is the patient's history suggestive of a new infection: |
| □ no |
| □ yes, if yes suspected source |
| □ Pneumonia, empyema |
| □ Urinary tract infection |
| □ Acute abdominal infection |
| □ Meningitis |
| □ Skin/soft tissue infection |
| □ Bone/joint infection |
| □ Wound infection |
| □ Bloodstream catheter infection |
| □ Endocarditis |
| □ Implantable device |
| □ Other |
| (2) Are any two signs and symptoms of infection present AND new to the patient? |
| □ Hyperthermia (>101°F or 38.3°C) |
| □ Hypothermia (<96.8°F or 36°C) |
| □ Tachycardia (>90 bpm) |
| □ Tachypnea (>20 bpm) |
| □ Acutely altered mental status |
| □ Leukocytosis (WBC count >12,000) |
| □ Leukopenia (WBC count <4,000) |
| □ >10% immature neutrophils |
|
|
| □ Obtain: serum lactate, blood cultures, CBC with diff, basic chemistry labs, bilirubin |
| □ Pertinent diagnostic tests ___________________________________ |
| (3) Are any of the following organ dysfunction criteria present AND acute: |
| □ SBP < 90 mmHg or MAP < 65 mmHg |
| □ SBP decrease >40 mmHg from baseline |
| □ Bilateral pulmonary infiltrates with a new (or increased) oxygen requirement to maintain SpO2 > 90% |
| □ Creatinine > 2 mg/dL or Urine Output < 0.5 mL/kg/hr for more than 2 hours |
| □ Bilirubin > 2 mg/dL |
| □ Platelet count <100,000 |
| □ Coagulopathy (INR > 1.5 or aPTT > 60 secs) |
| □ Serum lactate > 2 mmol/L |
|
|
|
|
|
|
Figure 1Sepsis patient daily progress note.
|
|
|
|
|
|
| Was sepsis present on admission (including ED stay)?: yes no |
| If no, date/time noted to be present: _________________________________________________________________________________________________________ |
| Source of sepsis:______________________________________________________________________________________________________________________________ |
| Evidence of infection (CXR, U/A, etc.): ___________________________________________________________________________________________________ |
| Positive blood cultures and date: ________________________________________________________________________________________________________ |
| End-organ damage:___________________________________________________________________________________________________________________________ |
|
|
|
|
| Initial antibiotic therapy:____________________________________________________________________________________________________________________ |
| Current antibiotic therapy and start date:__________________________________________________________________________________________________ |
| Anticipated duration of antibiotic therapy: _________________________________________________________________________________________________ |
| Route of administration and need for long-term access: ___________________________________________________________________________________ |
| Steroids considered/ Why given or not: _____________________________________________________________________________________________________ |
| Xigris considered/Why given or not:________________________________________________________________________________________________________ |
| Please provide a brief summary of why the patient needs to remain in the hospital and cannot receive further treatment as an outpatient. |
| ____________________________________________________________________________________________________________________________________________________ |
| ____________________________________________________________________________________________________________________________________________________ |
| ____________________________________________________________________________________________________________________________________________________ |
| Signature/Title Date /Time |
Patient characteristics between Code SMART and Non-Code SMART Groups.
| Code Smart | Non-Code Smart |
| |
|---|---|---|---|
|
|
| ||
| Mean (SD) Age (years) | 70 (2.26) | 61 (3.41) | .03 |
| Ethnicity | |||
| Caucasian | 1 (3%) | 3 (13%) | .16 |
| African American | 28 (82%) | 17 (71%) | .31 |
| Hispanic | 3 (9%) | 2 (8%) | .95 |
| Other | 2 (6%) | 2 (8%) | .73 |
| Gender (females) | 15 (44%) | 16 (67%) | .42 |
| Mean (SD) MEDS | 11.44 (.94) | 9.96 (1.13) | .32 |
| Sepsis | |||
| Urinary tract infection | 10 (29%) | 7 (29%) | .80 |
| Pneumonia | 18 (53%) | 8 (33%) | .25 |
| Cultures-positive | |||
| Blood | 13 (38%) | 8 (33%) | .96 |
| Urine | 16 (47%) | 7 (29%) | .26 |
| Shock present | 25 (74%) | 15 (63%) | .38 |
| Number of organs involved | |||
| 0 | 2 (6%) | 2 (8%) | .72 |
| 1 | 8 (24%) | 5 (21%) | .81 |
| 2 | 8 (24%) | 14 (50%) | .01 |
| 3 | 10 (29%) | 2 (8%) | .05 |
| 4+ | 6 (18%) | 1 (4%) | .13 |
| Leucopenia | 3 (9%) | 2 (8%) | .95 |
Difference of means test for compliance with sepsis bundles.
| Observed | Mean (SD) | |
|---|---|---|
| Code SMART | 34 | 6.50 (1.98) |
| Non-Code SMART | 24 | 5.21 (2.28) |
|
|
*P = 0.1.
Compliance with individual sepsis tasks.
| Code SMART proportion (S.D.)/ | Non-Code SMART proportion (S.D.)/ |
|
| |
|---|---|---|---|---|
| Antibiotics | .91 (.03)/34 | .54 (.10)/24 | −4.57 |
|
| Blood cultures | .91 (.03)/34 | .83 (.08)/24 | −1.86 | 0.07 |
| IV Fluids | 0.71 (.08)/34 | .50 (.10)/24 | −1.59 | 0.11 |
| Lactate | .94 (.04)/34 | .63.10/24 | −3.24 |
|
| CVP | 1 (0)/18 | .89 (.11)/9 | −1.44 | 0.16 |
| MV02 | .50 (.11)/22 | .38 (.18)/8 | −0.59 | 0.56 |
| Steroids | .55 (.08)/34 | .25 (.09)/24 | −2.41 |
|
| APC | .61 (.08)/34 | .41 (.10)/24 | −1.52 | 0.14 |
| Glucose | .62 (.08)/34 | .71 (.09)/24 | 0.71 | 0.48 |
| IPP | 1 (0)/7 | 1 (0)/12 | n/a | n/a |
Survival at discharge—Code SMART versus Non-Code SMART.
| Total patients | Patients alive at discharge | |
|---|---|---|
| Code SMART | 34 | 31 (91%) |
| Non-Code SMART | 24 | 17 (71%) |
|
|
*P < .05.
Model 1—logistic regression of mortality controlling for +/− use of Code SMART, MEDS, and leucopenia.
| Model 1 |
| Odds ratios | |
|---|---|---|---|
| Code SMART | 2.11 (.96) |
|
|
| MEDS | −.15 (.08) | 0.06 | 0.83 |
| Leucopenia | −2.00 (1.35) | 0.14 | 0.11 |
| Constant | 2.63 (.99) | 0.01 | — |
|
| 58 | ||
|
| 13.81 | 0.00 |
Model 2—Logistic regression of mortality controlling for +/− use of Code SMART, MEDS, leucopenia, and age.
| Model 2 |
| Odds ratios | |
|---|---|---|---|
| Code SMART | 3.492635 (1.345015) |
|
|
| MEDS | −.2171075 (.1181574) | 0.07 | 0.80 |
| Leucopenia | −2.628451 (1.594963) | 0.10 | 0.07 |
| Age | −.1090305 (.0494949) | 0.03 | 0.89 |
| Constant | 10.68133 (5.680985) | 0.06 | — |
|
| 58 | ||
|
| 23.94 | 0.00 |